Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Dysplasia in ulcerative colitis before and after liver transplantation

The latest issue of the Alimentary Pharmacology & Therapeutics investigates the fate of indefinite and low-grade dysplasia in ulcerative colitis and primary sclerosing cholangitis colitis before and after liver transplantation.

News image

Patients with primary sclerosing cholangitis and ulcerative colitis (UC) are at an increased risk of colorectal neoplasia, but it is unknown if liver transplantation alters neoplasia progression.

Dr Eaton and colleagues from Minnesota, USA examined the natural history of indefinite dysplasia (IND) and low-grade dysplasia that develop in patients with primary sclerosing cholangitis-UC with and without liver transplantation.

The team performed a retrospective review of patients with primary sclerosing cholangitis and UC between 1993 and 2011 who were diagnosed with IND or low-grade dysplasia before or after liver transplantation for primary sclerosing cholangitis.

The team's primary end point was neoplasia progression or persistent low-grade dysplasia.

5-ASA use was associated with a decreased risk of neoplasia progression
Alimentary Pharmacology & Therapeutics

The research team examined 96 patients.

For the IND group, multifocal lesions were significantly associated with time to neoplasia progression, while 5-aminosalicylate (5-ASA) use was protective.

For patients with low-grade dysplasia, multifocal lesions were significantly associated with the primary end point, while liver transplantation was protective.

Dr Eaton's team concluded, "In primary sclerosing cholangitis-UC patients with IND, 5-ASA use was associated with a decreased risk of neoplasia progression, regardless of transplant status."

"In contrast, multifocal IND and low-grade dysplasia were associated with neoplasia progression or persistent low-grade dysplasia."

"Patients who developed low-grade dysplasia following liver transplantation for primary sclerosing cholangitis were less likely to have progressive neoplasia or persistent low-grade dysplasia, compared with those who had not been transplanted."

Aliment Pharmacol Ther 2013: 38(8): 977987
08 October 2013

Go to top of page Email this page Email this page to a colleague

 03 May 2015

Advanced search
 01 May 2015 
NAFLD progression from steatosis to fibrosing-steatohepatitis
 01 May 2015 
Sleep and physical activity measured in Crohn's
 01 May 2015 
Dietary supplement hepatotoxicity
 30 April 2015 
Botulinum toxin A for the treatment of obesity
 30 April 2015 
Neoadjuvant chemoradiotherapy for esophageal cancer
 30 April 2015 
Risk factors for primary sclerosing cholangitis
 29 April 2015 
Liver enzyme elevations after anti-TNF therapy in IBD

 29 April 2015 
Hepatocellular carcinoma surveillance in HBV
 29 April 2015 
Response to sorafenib in hepatocellular carcinoma
 28 April 2015 
Risk factors of hepatocellular carcinoma
 28 April 2015 
Alcohol drinking and risk of liver cirrhosis
 28 April 2015 
Clinical outcomes after esophagectomy
 23 April 2015 
Gut microbiota modulation for alcoholic liver disease
 23 April 2015 
Moderate sodium restriction diet in cirrhosis
 23 April 2015 
Gastroesophageal junction disruption and obesity
 22 April 2015 
Hepatitis and mortality in hospitalized patients
 22 April 2015 
Magnetic sphincter augmentation for GERD
 22 April 2015 
Drug, herbal and dietary supplement hepatotoxicity
 21 April 2015 
Tracking colonoscopy surveillance intervals
 21 April 2015 
PPI increases risk of cryptogenic liver abscess
 21 April 2015 
Risk factors of postpartum bowel changes
 20 April 2015 
IBS after traveller's diarhea
 20 April 2015 
Economic impact of C. diff infection
 20 April 2015 
Adherence to Hep C treatments
 17 April 2015 
Synchronous colorectal advanced neoplasia
 17 April 2015 
PNPLA3 polymorphisms and NAFLD risk
 17 April 2015 
MELD score and colorectal resection
 16 April 2015 
Bleeding risk in colonic diverticulosis
 16 April 2015 
Minority use of high-volume hospitals for colorectal cancer
 16 April 2015 
Sleep and IBD
 15 April 2015 
Treatment of hepatocellular carcinoma
 15 April 2015 
Score predicts malignant bile duct obstruction
 15 April 2015 
Increased risk of Barrett esophagus
 14 April 2015 
Improving colorectal cancer screening uptake
 14 April 2015 
Colorectal cancer presenting under the age of 50
 14 April 2015 
Functional constipation vs constipation predominant IBS
 13 April 2015 
Fecal transplant for C. difficile
 13 April 2015 
Immune based treatments for HCC
 13 April 2015 
CRP and acute diverticulitis
 10 April 2015 
Adjuvant therapy after rectal cancer
 10 April 2015 
Viral outcomes in HCV infection
 10 April 2015 
Hypnotherapy for IBS
 09 April 2015 
Male IBD patients wishing to conceive
 09 April 2015 
Screening programs based on the fecal immunochemical test
 09 April 2015 
Management of esophageal food impaction
 08 April 2015 
Ambulatory hemorrhoidal surgery
 08 April 2015 
Iron fortification and gut inflammation
 08 April 2015 
Nonceliac gluten sensitivity
 07 April 2015 
Interventions for eosinophilic esophagitis
 07 April 2015 
Treatment of Hep C virus
 07 April 2015 
Endoscopic managements of GI bleeds
 06 April 2015 
Risk stratifying Barrett's esophagus
 06 April 2015 
Cost-effectiveness of HCV
 06 April 2015 
Treatment for rectal cancer
 03 April 2015 
Predicting advanced cancer in Barrett's
 03 April 2015 
Vitamin D deficiency and Hep B outcomes
 03 April 2015 
Hepatocellular carcinoma surveillance in cirrhosis
 02 April 2015 
Physical activity and NAFLD
 02 April 2015 
Genetic risk for Crohn's disease
 02 April 2015 
EUS for detection of pancreatic neuroendocrine tumors

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us